| Compound | Dihexa |
|---|---|
| Category | Angiotensin IV analog |
| Class | Neuro, Nootropic, and Cosmetic Peptides |
| Evidence tier | Preclinical |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
Dihexa is catalogued here as a angiotensin iv analog and graded at the "Preclinical" evidence tier. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.
An angiotensin IV analog studied for synaptogenesis in laboratory models, discussed in nootropic communities despite having no human data.
Mechanism of Action
Dihexa is reported to be a potent hepatocyte growth factor receptor (c-Met) agonist, promoting dendritic spine formation in cell and animal studies.
Research and Evidence
Evidence is exclusively preclinical. Concerns about hepatotoxicity flagged in early work have not been characterized in humans.
Safety and Side Effects
No human safety data; potent trophic signaling makes unmonitored use a poor risk.
Frequently Asked Questions
What is the evidence tier of Dihexa?
Dihexa is graded "Preclinical" on this site. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.
Is Dihexa an approved medicine?
No. Preclinical means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for Dihexa?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — search for Dihexa studies (none registered). [source]
Evidence tier: Preclinical · Last reviewed: 2026-09-05 · Sources cited below.